G Antar Farag, AzzaA Hammam, MostafaR Al-Sharaky, DaliaA Hassan, ReemN ElShafey, EmanA Ali, Nehal2020-03-172020-03-1720191687-1537https://doi.org/10.4103/JEWD.JEWD_4_19https://cutt.ly/ctjL3EiMSA Google ScholarChemokine ligand 22 (CCL22) is a heparin-binding immunomodulator protein that plays an important role in a variety of autoimmune diseases. Narrow-band ultraviolet B (NB-UVB) therapy was considered a cornerstone in the treatment of vitiligo. However, the mechanism of action of NB-UVB in vitiligo has not been completely elucidated. Objective To study the hypothesized role of CCL22 in vitiligo etiopathogenesis and to detect its possible role in NB-UVB-induced pigmentation in vitiligo through its lesional immunohistochemical evaluation in patients with vitiligo before and after ultraviolet B phototherapy.enchemokine ligand 22narrow band ultraviolet BvitiligoArticlehttps://doi.org/10.4103/JEWD.JEWD_4_19